Relevant bibliographies by topics / Eudragit

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Eudragit'

Author: Grafiati
Published: 4 June 2021
Last updated: 25 April 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Eudragit.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Eudragit"

1

Hussien, Ahmed Abbas. "Preparation and Evaluation of Oral Microsponge Drug Delivery System of Ketoconazole." Al Mustansiriyah Journal of Pharmaceutical Sciences 14, no. 1 (June 1, 2014): 1–8. http://dx.doi.org/10.32947/ajps.v14i1.119.

Full text
Abstract:
In oral applications, the microsponge system has been shown to increase the rate of solubilization of poorly water-soluble drugs by entrapping such drugs in the microsponge system's pores.Because these pores are very small, the drug is in effect reduced tomicroscopic particles and increased surface area thus greatly increases the rate ofsolubilization.This investigation was done to increase solubility and then bioavialibility of poorly soluble ketoconazole (BCS class II drug) by preparing it as microsponges by quasi emulsionsolvent technique using different types of Eudragits as Eudragit E 100, Eudragit RS or Eudragi tRL. Physicochemical interaction between drug and excipients as individual one,physical mixture and prepared microsponge has been evaluated using Fourier transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) which indicates theabsence of interaction between them. The1: 0.1 ratio drug: Eudragit E 100 at stirring rate of 2000 rpm (F1b) was found to give the best production yield of 80.46±2.41, entrapment efficiency of 70.84%±1.71, and smallest particle size of 57.42±2.26 μm. Scanning electron microscopy of F1b at magnification of 1000x and 50000x shows the presence of drug as nanocrystals inside microsponge. All prepared formulas shows good flow properties indicated the possibility of capsule formulation which show significant (P<0.05) high drug release percent in 0.1 HCl compared with traditional Nizoral® oral tablet (83.15%±1.10) but Eudragit E (F1b ) shows the best drug release percent of 100±0.91 at 20 minutes. Finally, the overall obtained data revealed the feasibility of preparing fast release ketaconazole as microsponges in oral capsules dosage form.
APA, Harvard, Vancouver, ISO, and other styles
2

Ranpise, N. S., S. S. Somavanshi, R. K. Bhujbal ., and Y. M. Jagtap. "DEVELOPMENT OF SUSTAINED RELEASE TABLET OF METFORMIN HYDROCHLORIDE BY AQUEOUS COATING." INDIAN DRUGS 49, no. 02 (February 26, 2012): 26–32. http://dx.doi.org/10.53879/id.49.02.p0026.

Full text
Abstract:
The aim of present work was to develop a metformin hydrochloride sustained release tablet by aqueous coating. Eudragit RL and Eudragit RS were used for coating of tablets. Eudragit RL having 10% and Eudragit RS having 5% of functional quaternary ammonium groups, which give rise to pH independent permeability of the polymer. Metformin hydrochloride uncoated tablets were prepared by wet granulation technique. Tablets were coated with blends of Eudragit RS30D and Eudragit RL30D in 5:1 and in 3:1 ratios at different coating level viz. 7%, 5%, 3%, 1.5%, 1%. Two dissolution media: pH 1.2 and pH 6.8 phosphate buffer were employed for in vitro release behaviors of metformin hydrochloride tablets. Coating with blends of Eudragit RS 30D and Eudragit RL 30D in 5:1 and in 3:1 ratio at 1% and at 3% showed sustained release effect for 12 h. The two Eudragit polymers with different features as coating materials produced the desired results.
APA, Harvard, Vancouver, ISO, and other styles
3

Moustafine, R. I., T. V. Kabanova, V. A. Kemenova, and G. Van den Mooter. "Characteristics of interpolyelectrolyte complexes of Eudragit E100 with Eudragit L100." Journal of Controlled Release 103, no. 1 (March 2005): 191–98. http://dx.doi.org/10.1016/j.jconrel.2004.11.031.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Han, Min, Qin Yu, Xuerong Liu, Fuqiang Hu, and Hong Yuan. "Preparation and Characterization of a Novel Aqueous Dispersion for Enteric Coating of Pantoprazole Sodium Pellets." Acta Pharmaceutica 68, no. 4 (December 1, 2018): 441–55. http://dx.doi.org/10.2478/acph-2018-0035.

Full text
Abstract:
Abstract The purpose of this work was to investigate a novel aqueous dispersion (Eudragit® L100-55) f or e nteric c oating o f drugs. Three different casting solutions, Eudragit® L100-55 aqueous dispersion, Eudragit® L 100-55 o rganic s olution, and Eudragit® L30D-55 aqueous dispersion, were used to prepare free films by the casting method. Drug-loaded pellets, prepared by the extrusion-spheronization method, were coated with one of these three coating solutions using the fluidized-bed spray coating technology. Properties of the free films were thoroughly investigated. Films formed by Eudragit® L100-55 aqueous dispersions showed similar properties to those formed by Eudragit® L100-55 organic solution regarding thermodynamic properties, moisture permeability, solubility and acid tolerance ability. Furthermore, the performance of the novel film was better than that formed by Eudragit® L30D-55 aqueous dispersion. Among the three enteric coating solutions, Eudragit® L100- 55 aqueous dispersion will be a promising aqueous dispersion for enteric coating and can be used in the development of enteric-coated preparations.
APA, Harvard, Vancouver, ISO, and other styles
5

Ha, Eun-Sol, Du Hyung Choi, In-hwan Baek, Heejun Park, and Min-Soo Kim. "Enhanced Oral Bioavailability of Resveratrol by Using Neutralized Eudragit E Solid Dispersion Prepared via Spray Drying." Antioxidants 10, no. 1 (January 11, 2021): 90. http://dx.doi.org/10.3390/antiox10010090.

Full text
Abstract:
In this study, we designed amorphous solid dispersions based on Eudragit E/HCl (neutralized Eudragit E using hydrochloric acid) to maximize the dissolution of trans-resveratrol. Solid-state characterization of amorphous solid dispersions of trans-resveratrol was performed using powder X-ray diffraction, scanning electron microscopy, and particle size measurements. In addition, an in vitro dissolution study and an in vivo pharmacokinetic study in rats were carried out. Among the tested polymers, Eudragit E/HCl was the most effective solid dispersion for the solubilization of trans-resveratrol. Eudragit E/HCl significantly inhibited the precipitation of trans-resveratrol in a pH 1.2 dissolution medium in a dose-dependent manner. The amorphous Eudragit E/HCl solid dispersion at a trans-resveratrol/polymer ratio of 10/90 exhibited a high degree of supersaturation without trans-resveratrol precipitation for at least 48 h by the formation of Eudragit E/HCl micelles. In rats, the absolute oral bioavailability (F%) of trans-resveratrol from Eudragit E/HCl solid dispersion (10/90) was estimated to be 40%. Therefore, trans-resveratrol-loaded Eudragit E/HCl solid dispersions prepared by spray drying offer a promising formulation strategy with high oral bioavailability for developing high-quality health supplements, nutraceutical, and pharmaceutical products.
APA, Harvard, Vancouver, ISO, and other styles
6

Ha, Eun-Sol, Du Hyung Choi, In-hwan Baek, Heejun Park, and Min-Soo Kim. "Enhanced Oral Bioavailability of Resveratrol by Using Neutralized Eudragit E Solid Dispersion Prepared via Spray Drying." Antioxidants 10, no. 1 (January 11, 2021): 90. http://dx.doi.org/10.3390/antiox10010090.

Full text
Abstract:
In this study, we designed amorphous solid dispersions based on Eudragit E/HCl (neutralized Eudragit E using hydrochloric acid) to maximize the dissolution of trans-resveratrol. Solid-state characterization of amorphous solid dispersions of trans-resveratrol was performed using powder X-ray diffraction, scanning electron microscopy, and particle size measurements. In addition, an in vitro dissolution study and an in vivo pharmacokinetic study in rats were carried out. Among the tested polymers, Eudragit E/HCl was the most effective solid dispersion for the solubilization of trans-resveratrol. Eudragit E/HCl significantly inhibited the precipitation of trans-resveratrol in a pH 1.2 dissolution medium in a dose-dependent manner. The amorphous Eudragit E/HCl solid dispersion at a trans-resveratrol/polymer ratio of 10/90 exhibited a high degree of supersaturation without trans-resveratrol precipitation for at least 48 h by the formation of Eudragit E/HCl micelles. In rats, the absolute oral bioavailability (F%) of trans-resveratrol from Eudragit E/HCl solid dispersion (10/90) was estimated to be 40%. Therefore, trans-resveratrol-loaded Eudragit E/HCl solid dispersions prepared by spray drying offer a promising formulation strategy with high oral bioavailability for developing high-quality health supplements, nutraceutical, and pharmaceutical products.
APA, Harvard, Vancouver, ISO, and other styles
7

dos Santos, Juliana, Guilherme Silveira da Silva, Maiara Callegaro Velho, and Ruy Carlos Ruver Beck. "Eudragit®: A Versatile Family of Polymers for Hot Melt Extrusion and 3D Printing Processes in Pharmaceutics." Pharmaceutics 13, no. 9 (September 8, 2021): 1424. http://dx.doi.org/10.3390/pharmaceutics13091424.

Full text
Abstract:
Eudragit® polymers are polymethacrylates highly used in pharmaceutics for the development of modified drug delivery systems. They are widely known due to their versatility with regards to chemical composition, solubility, and swelling properties. Moreover, Eudragit polymers are thermoplastic, and their use has been boosted in some production processes, such as hot melt extrusion (HME) and fused deposition modelling 3D printing, among other 3D printing techniques. Therefore, this review covers the studies using Eudragit polymers in the development of drug delivery systems produced by HME and 3D printing techniques over the last 10 years. Eudragit E has been the most used among them, mostly to formulate immediate release systems or as a taste-masker agent. On the other hand, Eudragit RS and Eudragit L100-55 have mainly been used to produce controlled and delayed release systems, respectively. The use of Eudragit polymers in these processes has frequently been devoted to producing solid dispersions and/or to prepare filaments to be 3D printed in different dosage forms. In this review, we highlight the countless possibilities offered by Eudragit polymers in HME and 3D printing, whether alone or in blends, discussing their prominence in the development of innovative modified drug release systems.
APA, Harvard, Vancouver, ISO, and other styles
8

Thakur, Nishant, Bhupinder Kaur, Manish Goswami, and Chandan Sharma. "Compatibility studies of the Thiocolchicoside with Eudragit RLPO, Eudragit E100 and Eudragit L100 using thermal and non-thermal methods." Drug Combination Therapy 4, no. 1 (2022): 1. http://dx.doi.org/10.53388/dct2021100301.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Jun, Hee-Sook, Gongdeuk Bae, Young Tag Ko, and Yoon Sin Oh. "Cytotoxicity and Biological Efficacy of Exendin-4-Encapsulated Solid Lipid Nanoparticles in INS-1 Cells." Journal of Nanomaterials 2015 (2015): 1–6. http://dx.doi.org/10.1155/2015/753569.

Full text
Abstract:
Exendin-4 (Ex-4), a peptide of glucagon-like peptide-1 receptor agonist, is a potent insulinotropic agent and alternative drug delivery systems to increase therapeutic utility have been explored. We developed exendin-4-encapsulated solid lipid nanoparticles (Eudragit Ex-4 SLNs) and compared the effects of Eudragit Ex-4 SLNs with those of native Ex-4 on INS-1 cells. We observed no significant toxic effects of nanoparticles at concentrations from 1 nM to 100 nM. Similar to Ex-4, Eudragit Ex-4 SLNs stimulated the production of cyclic AMP at 10 nM. Moreover, unlike treatment with the vehicle, treatment with 10 nM Eudragit Ex-4 SLNs increased insulin mRNA levels and insulin secretion. These insulinotropic effects of Eudragit Ex-4 SLNs were comparable to those of Ex-4. Thus, ourin vitroresults suggest that the biological effects of Eudragit Ex-4 SLNs are similar to those of Ex-4, and furtherin vivopharmacokinetic studies are required to propose an alternative sustained release drug system.
APA, Harvard, Vancouver, ISO, and other styles
10

Quan, Ji Shan, Hu Lin Jiang, Yun Jaie Choi, Mi Kyong Yoo, and Chong Su Cho. "Thiolated Eudragit-Coated Chitosan Microspheres as an Oral Drug Delivery System." Key Engineering Materials 342-343 (July 2007): 445–48. http://dx.doi.org/10.4028/www.scientific.net/kem.342-343.445.

Full text
Abstract:
The aim of this study is to prepare mucoadhesive chitosan microspheres for protein drug to deliver to intestine through oral administration. The thiolated Eudragit was synthesized by reaction between L-cysteine hydrochloride and Eudragit® L-100. About 8 mol-% of cysteine was introduced to the Eudragit-cysteine conjugate. The conjugate was used to coat bovine serum albumin (BSA)-loaded chitosan microspheres. The average particle sizes of BSA-loaded thiolated Eudragit-coated chitsoan microspheres (TECMs) were 4.06±0.74 .m and the uniform sizedistribution was shown. The in vitro release of BSA from BSA-loaded TECMs was pH-dependent. Our results indicated that thiolated Eudragit might be a good candidate as a coating material for oral delivery of protein drug owing to mucoadhesive and pH-sensitive properties.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Eudragit"

1

Frank, Luiza Abrahão. "Avaliação da performance e caracterização in vitro de diferentes hidrogéis de quitosana contendo nanocápsulas poliméricas para aplicação vaginal." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2014. http://hdl.handle.net/10183/144066.

Full text
Abstract:
A via de administração vaginal pode ser considerada uma alternativa para diversos tratamentos, tanto de ação farmacológica local como sistêmica. No entanto, o tempo de permanência do fármaco no local da aplicação e a eficácia esperada representam um desafio para o desenvolvimento de formulações. O objetivo deste trabalho foi desenvolver nanocápsulas de superfície catiônica (EUDRAGIT® RS 100) ou aniônica (EUDRAGIT® S 100), contendo ou não o marcador de fluorescência Vermelho do Nilo como um modelo de fármaco lipofílico, e incorporar essas partículas em hidrogéis de quitosana, a fim de aumentar o tempo de residência da formulação na mucosa vaginal, devido às propriedades mucoadesivas desse polímero. Diversas formulações foram preparadas com concentrações crescentes de quitosana e analisadas em termos de pH e comportamento reológico, a fim de selecionar a mais adequada para aplicação vaginal. Os hidrogéis foram produzidos com quitosana 2,5% p/p, com ou sem nanocápsulas. Foi avaliada a aderência (mucoadesividade e perfil lavabilidade) e a capacidade de penetração (microscopia confocal e extração seguido de quantificação do vermelho do nilo) das formulações quando aplicadas em mucosa vaginal de porcas. As suspensões de nanocápsulas apresentaram diâmetro em torno de 200 nm e potencial zeta entre +13 mV (NC-RS) e -13 mV( NC-S) e valores de pH entre 5,1 e 6,2. A formulação de quitosana apresentou viscosidade característica e pH ácido (em torno de 4,5), ideal para aplicação vaginal. Os testes de mucoadesão mostraram que as formulações propostas contendo nanocápsulas poliméricas apresentaram maior adesividade em mucosa vaginal em comparação com a formulação composta somente de quitosana. Através do experimento de lavabilidade não foram encontradas diferenças significativas entre as formulações. No entanto, as técnicas de microscopia confocal e a quantificação após a extração de fluorescência a partir da mucosa demonstraram uma maior penetração de vermelho do nilo quando nanoencapsulado, especialmente em nanocápsulas catiônicas. As formulações desenvolvidas com base no veículo do hidrogel de quitosana e nanocápsulas poliméricas, especialmente as nanocápsulas catiônicas, demonstraram aplicabilidade para a entrega de substâncias hidrofóbicas pela via vaginal. Palavras-chave: quitosana, nanocápsuas, via vaginal, EUDRAGIT® RS100, EUDRAGIT® S100.
The vaginal route of administration might be an alternative for several treatments, either for local or systemic pharmacological effect. However, the permanence of the drug at the site of application and its expected effectiveness represent a challenge in the development of formulations. Thus, the objective of this work was to develop nanocapsules with cationic or anionic surface charge, containing or not nile red as a model of lipophilic substance, and to incorporate such particles into chitosan vehicle in order to increase the residence time of the formulation due to chitosan mucoadhesive properties. Several formulations prepared with increasing chitosan concentrations were analyzed in terms of pH and rheological behaviour in order to select the most suitable one for vaginal application. Gel formulations were produced with chitosan at 2.5% w/w, with or without nanocapsules. The adhesion (tensile stress test and washability profile) and penetration enhancement properties (confocal microscopy- CLSM and extraction followed by quantification) of the formuations, when applied on porcine vaginal mucosa, were evaluated. The nanocapsule suspensions presented adequate properties and pH values around 5.1 and 6.2. The chitosan formulation presented a characteristic viscosity and an acid pH (around 4.5), which is suitable for vaginal application. Mucoadhesion tests showed that the proposed formulations containing polymeric nanocapsules had higher adhesion to the vaginal mucosa in comparison with the formulation containing only chitosan. The washability evaluation showed no significant differences between the formulations. However, the confocal microscopy and the fluorescence quantification after extraction from the mucosa showed higher penetration of nile red when nanoencapsulated, especially into cationic-charged nanocapsules. The formulations developed, based on chitosan gel vehicle and polymeric nanocapsules, especially the cationic nanocapsules, demonstrated applicability for the vaginal delivery of hydrophobic substances.
APA, Harvard, Vancouver, ISO, and other styles
2

Souza, Marina Claro de. "Microencapsulação do sulfóxido de albendazol: uma estratégia para otimização da terapia das parasitoses." Universidade de São Paulo, 2009. http://www.teses.usp.br/teses/disponiveis/60/60137/tde-21032009-094902/.

Full text
Abstract:
As parasitoses causadas por helmintos constituem um grave problema sanitário, tanto para os seres humanos quanto para os animais, além de gerar grandes prejuízos econômicos. O sulfóxido de albendazol é um fármaco anti-helmíntico de amplo espectro, largamente utilizado na medicina veterinária, veiculado pelas vias oral e parenteral, mediante a utilização de formas farmacêuticas convencionais. Apresenta biodisponibilidade baixa e irregular em função de sua pouca solubilidade nos fluidos biológicos. Para a manutenção da concentração plasmática e completa eliminação dos parasitos, são necessárias administrações reiteradas, ocasionando transtornos decorrentes do manejo freqüente dos animais e do aumento do custo da terapia. O presente trabalho teve como objetivo desenvolver e caracterizar um sistema microparticulado para liberação sustentada de sulfóxido de albendazol, de modo que este pudesse permanecer no organismo dos animais pelo tempo suficiente para a completa eliminação dos parasitos após uma única administração. Os sistemas foram obtidos a utilizando as técnicas de spray-drying e emulsificação / evaporação de solvente, tendo sido utilizados os polímeros Eudragit RS 30 D® e Eudragit RS PO®, respectivamente. As micropartículas obtidas foram caracterizadas com relação ao tamanho, à morfologia e à eficiência de encapsulação. Através da técnica de emulsificação / evaporação de solvente, foram obtidas partículas com diâmetro médio inferior a 300nm, estreita faixa de distribuição de tamanho e eficiência de encapsulação de aproximadamente 60%. Os resultados do estudo in vitro do perfil de liberação do fármaco a partir das micropartículas obtidas mostraram que, apesar de o sistema desenvolvido não ter sido capaz de sustentar a liberação do fármaco, o mesmo promoveu um aumento significativo da solubilidade do sulfóxido de albendazol em pH 7,4, fato este que pode contribuir para o aumento da biodisponibilidade do mesmo após administração parenteral.
The helminthosis are a serious sanitary problem, as for the men than for the animals, besides the great economic lacks. Albendazole sulphoxide is an antihelminthic drug with broad spectrum of action, widely used at veterinarian medicine, throw oral and parentereal vies, in conventional pharmaceutical dosages. It has low and irregular bioavailability due its low solubility in the biological fluids. For the maintenance of the plasmatic concentration and complete elimination of the parasites, it is required several administrations, creating many troubles due the frequent handling of the animals and increase in the costs of the therapy. The present work had as objective to develop and characterize microparticles for sustained release of albendazole sulphoxide, in order that the drug could be for a longer time in the animals organisms and the parasites could be eliminated after just one administration. The referred microparticles were obtained from the spray-drying and emulsification / evaporation of solvent techniques, using the polymers Eudragit RS 30 D® and Eudragit RS PO®, respectively. The obtained systems were characterized considering size, morphology and encapsulation efficiency. Using the emulsification / evaporation of solvent technique, it was prepared microparticles with medium diameter under 300nm, narrow range of size distribution and encapsulation efficiency of about 60%. The results of the in vitro release profile study of the drug from the prepared microparticles showed that besides the developed system was not be able to sustain the drug delivery, it was able to improve significantly the solubility of albendazole sulphoxide at pH 7.4, what can be useful to improve its parenteral bioavailability.
APA, Harvard, Vancouver, ISO, and other styles
3

Wagner, Karl Gerhard. "Tablettierung überzogener Pellets auf einer Hochleistungsrundlauftablettenpresse unter Einsatz von Eudragit FS 30 D /." [S.l. : s.n.], 1999. http://www.gbv.de/dms/bs/toc/309513251.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Albers, Jessica. "Hot-melt extrusion with poorly soluble drugs." Göttingen Cuvillier, 2008. http://d-nb.info/990809501/04.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mandal, Bivash. "Preparation and Physicochemical Characterization of Eudragit® RL100 Nanosuspension with potential for Ocular Delivery of Sulfacetamide." University of Toledo / OhioLINK, 2010. http://rave.ohiolink.edu/etdc/view?acc_num=toledo1271430956.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Socha, Marie. "Apport des nanotechnologies dans le domaine des peptides et des protéines : Application à l’absorption par voie orale et à la furtivité." Thesis, Nancy 1, 2008. http://www.theses.fr/2008NAN10118/document.

Full text
Abstract:
Les nanoparticules constituent une forme médicamenteuse d’avenir dans le domaine pharmaceutique. Capables de véhiculer de nombreux principes actifs, elles peuvent les libérer dans l’organisme après administration in vivo mais aussi les piloter vers des cibles prédéfinies. Ce travail repose sur la préparation, par une technique de double émulsion, de nanoparticules constituées de deux polymères : la poly-e-caprolactone et un polymère polyacrylique et polycationique (Eudragit® RS). La première partie a consisté en la mise au point de nanoparticules encapsulant de l’insuline et capables de la libérer in vitro et in vivo. Ces nanoparticules ont développé une activité hypoglycémiante après administration orale. En effet, l’inconvénient majeur du traitement du diabète par l’insuline reste un mode d’administration contraignant pour le diabétique : la voie injectable. La possibilité d’administrer l’insuline par voie orale constituerait un progrès révolutionnaire dans le domaine de la diabétologie. Les nanoparticules préparées ont donc démontré leur capacité à diminuer le glucose sanguin de rats diabétiques après administration orale. Le mécanisme de passage de l’insuline semble être dû à un contact intime entre le mucus chargé négativement et les nanoparticules de charge opposée créant ainsi un fort gradient local de concentration. La seconde partie du travail a consisté en la mise au point de nanoparticules dites furtives c’est à dire capables d’éviter leur reconnaissance par le système phagocytaire mononucléé après administration intraveineuse. L’objectif était de créer un procédé innovant de furtivité reposant sur la formation d’interactions électrostatiques entre l’héparine, glycosaminoglycane polyanionique, et l’Eudragit® RS, polymère polycationique. Le potentiel de furtivité a été démontré par l’augmentation in vivo de la demi-vie plasmatique de deux principes actifs de natures différentes : le chlorhydrate de propranolol et l’insuline
Nanoparticles are innovative dosage forms in drug delivery. They can act as prolonged release dosage forms but they also have the potentiality to target specific physiological compartments after in vivo administration. This thesis is based on the preparation of nanoparticles according to a double emulsion process. The nanoparticles are formed of two biocompatible polymers: poly-e-caprolactone and a polyacrylic and polycationic polymer (Eudragit® RS). The first part describes the development of insulin-loaded nanoparticles able to release insulin both in vitro and in vivo. It has been demonstrated that such nanoparticles incorporated high amounts of insulin and were able to display a hypoglycemic activity after oral administration. It is well known that the major drawback of diabetes treatment remains the injectable administration route for insulin. The ability to administer insulin orally would be a tremendous progress in the field of diabetes. Our prepared nanoparticles have demonstrated their ability to reduce blood glucose in diabetic rats after oral administration. It is believed that the positively charged insulin-loaded nanoparticles may interact with the negatively charged mucus and create a high local gradient concentration which would favor the intestine permeation. The second part of the thesis was devoted to the development of stealth nanoparticles able to avoid the recognition by the mononuclear phagocytosis system after intravenous administration. The objective was to create a new system based on the formation of electrostatic interactions between heparin, a polyanionic glycosaminoglycane, and Eudragit® RS, polycationic polymer. The stealth potential has been demonstrated by increasing the in vivo plasma half-life of two drugs namely propranolol hydrochloride and insulin
APA, Harvard, Vancouver, ISO, and other styles
7

Schichtel, Julian [Verfasser]. "Determination of the dissolution behavior of celecoxib-eudragit E 100-nanoparticles using cross-flow filtration / Julian Schichtel." Mainz : Universitätsbibliothek Mainz, 2017. http://d-nb.info/1122860242/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Verones, Daniel Antonio Garbim. "Desenvolvimento de micropartículas gastro-resistentes contendo azitromicina por spray-drying." Universidade de São Paulo, 2010. http://www.teses.usp.br/teses/disponiveis/60/60137/tde-17112010-232035/.

Full text
Abstract:
A azitromicina é um antibiótico da classe dos macrolídeos utilizado principalmente no tratamento de infecções de pele e do trato respiratório. Suas propriedades farmacocinéticas lhe conferem ampla distribuição e acumulação tecidual. Devido à sua baixa biodisponibilidade (37%) e instabilidade ao pH ácido, foram investigadas alternativas para o desenvolvimento de microparticulados com propriedade gastro-resistente para aplicação em diferentes formas farmacêuticas. As micropartículas de azitromicina foram obtidas pela técnica de secagem por pulverização (spray-drying) com o polímero pH-dependente Eudragit® L30-D55 e trietilcitrato como plastificante. O desenvolvimento experimental seguiu um planejamento fatorial tipo Box-Behnken de quatro variáveis em três níveis. As micropartículas foram caracterizadas pela densidade aparente, densidade compactada, fator de Hausner, índice de Carr, ângulo de repouso e cromatografia líquida. O processo de secagem foi avaliado pelo rendimento e recuperação da azitromicina. A partir das características físicas do microparticulado e o rendimento do processo foram escolhidas três micropartículas para avaliação mais detalhada, contendo 15, 30 e 45% de polímero de revestimento sobre a concentração de azitromicina dihidrato. Estas foram avaliadas por difração de raios-X, calorimetria, infra-vermelho, microscopia eletrônica de varredura e teste de dissolução. Os fatores que mais influenciaram o processo de secagem e obtenção das micropartículas foram a concentração de Eudragit® L30D-55 e a temperatura do ar de secagem, sendo que, quanto menor a concentração de polímero e maior a temperatura de secagem melhores foram os rendimentos do processo. A recuperação da azitromicina para todas as micropartículas foram superiores a 80%. As micropartículas apresentaram baixa densidade aparente, porém com propriedades de fluxo que variaram de bom a excelente na maioria das condições de preparação. As avaliações por calorimetria e difração de raios-X sugerem que a azitromicina está encapsulada. Isto pode ser confirmado por meio das imagens da microscopia eletrônica de varredura que revelaram estruturas esféricas e uniformes. As micropartículas com maiores concentrações de polímero apresentaram as melhores características com proteção gástrica, acima de 50%, e são candidatas promissoras para o desenvolvimento de formas farmacêuticas sólidas orais gastro-resistentes contendo azitromicina.
The azithromycin is an antibiotic of the macrolide class used in cutaneous and respiratory infections treatments. Its pharmacokinetics properties confer a large cell distribution and accumulation in tissues. Due to its small bioavailability (37%) and acid pH instability, alternatives to the development of gastric-resistance microparticles to be uses in different pharmaceuticals forms were investigated. Azithromycin microparticles were obtained through spray-drying technique with the pH-dependent polymer Eudragit® L30-D55 and triethyl citrate as plasticizer. The experimental development followed a factorial planning Box-Behnken with four factors in three levels. The microparticles were characterized by bulk density, tapped density, Hausner ratio, Carr index, repose angle and HPLC. The drying process was evaluated by azithromycin yield and recover. From the microparticles physics parameters and the process yield, three samples were chosen to be better evaluated. The samples contained 15, 30 and 45% of coat polymer over azithromycin dehydrate. They were evaluated by X-ray powder diffraction (XRPD), calorimetry, infrared, surface electronic microscopy (SEM) and dissolution assay. The factors that most affected the drying process and the microparticles development were Eudragit® L30D-55 concentration and drying air temperature, and lower was the polymer amount and higher was the drying air temperature, better was the process yield. The azithromycin recover for all microparticles were superior to 80%. The microparticles presented low bulk density, but good flow properties for the great part of the samples. The calorimetry and the XRPD evaluations suggest that azithromycin is encapsulated, what can be confirmed through SEM pictures, which showed uniform and spherical structures. The microparticles with higher polymers concentrations showed the best characteristics with gastric protection above 50% and they are promising candidates to the development of oral solid pharmaceutical forms containing gastro-resistant azithromycin.
APA, Harvard, Vancouver, ISO, and other styles
9

Marais, Etienne Barend. "Permeation of excised intestinal tissue by insulin released from Eudragit® L100/Trimethyl chitosan chloride microspheres /E.B. Marais." Thesis, North-West University, 2013. http://hdl.handle.net/10394/9676.

Full text
Abstract:
The purpose of this research project was to develop and characterise matrix type microspheres prepared from Eudragit® L100, containing insulin as model peptide drug as well as an absorption enhancer, N-trimethyl chitosan chloride (TMC), to improve intestinal absorption via the paracellular route. Insulin loaded microspheres were prepared using a single water in oil emulsification/evaporation method in accordance with a fractional factorial design (23) and subsequently characterised in terms of morphology as well as internal structure. Also, insulin and TMC loading were determined using a high pressure liquid chromatography analysis (HPLC) and colorimetric assay, respectively. Scanning electron microscopic characterisation revealed that most microsphere formulations showed a spherical shape and smooth surface with a sponge-like internal structure as well as relatively good homogeneity in terms of size distribution. Insulin loading ranged from 27.9 ± 14.25 – 52.4 ± 2.72% between the different formulations. TMC loading was lower than for insulin and ranged from 29.1 ± 3.3 - 37.7 ± 2.3% between the different formulations. The pronounced difference in insulin and TMC loading between the microsphere formulations is probably the result of the multitude parameters involved as well as the complex physicochemical processes which govern emulsification/solvent evaporation. Based on the microsphere characterisation results, two formulations were selected (i.e. B and F) for further characterisation (i.e. particle size distribution, dissolution behaviour, and enteric nature) and for in vitro evaluation of insulin transport across excised Fischer (FSR) rat intestinal tissue using a Sweetana-Grass diffusion chamber. Particle size analysis by means of laser light diffraction of the two selected microsphere formulations revealed that the mean particle size (based on volume) ranged from 135.7 ± 41.05 to 157.3 ± 31.74 m. Dissolution results for microsphere Formulations B and F revealed that both insulin and TMC were released from the microsphere formulations in an alkaline environment (pH 7.4). The mean dissolution time (MDT) for insulin ranged from 34.5 ± 4.01 to 42.6 ± 9.06 min, while the MDT for TMC ranged from 1.2 ± 1.73 to 6.8 ± 6.42 min. Statistical analysis revealed no significant differences in the MDT of either insulin or TMC (p-value > 0.05) between the two formulations, although the difference between insulin and TMC of each formulation was significant (p-value < 0.05). Microsphere formulations B and F released 36.92 and 48.21% of their total drug content over a period of 1 h in 0.1 M HCl. Microsphere Formulation B showed 8.3 ± 0.52% and formulation F 8.9 ± 2.26% transport of the initial insulin dose after a period of 120 min across excised rat intestinal tissue. The increase in insulin transport by the microsphere formulations compared to that of the control group (i.e. insulin alone) correlated well with the decrease in transepithelial electrical resistance (TEER) caused by the microsphere formulations. The transport of insulin from Formulations B and F represented transport enhancement ratios of 10.67 and 9.68, respectively. Insulin loaded EudragitL100 microspheres containing TMC were successfully prepared by emulsification/solvent evaporation that demonstrated promising potential to serve as oral drug delivery systems for insulin. The microspheres exhibited improved insulin permeability across intestinal epithelial tissue; however, its enteric properties should be improved and clinical effectiveness need to be confirmed by future in vivo studies.
Thesis (MSc (Pharmaceutics))--North-West University, Potchefstroom Campus, 2013.
APA, Harvard, Vancouver, ISO, and other styles
10

Zafar, Nadiah. "Microparticules biodégradables à morphologie éponge pour applications thérapeutiques et cosmetotextile." Thesis, Lyon, 2016. http://www.theses.fr/2016LYSE1068/document.

Full text
Abstract:
L'objectif de cette thèse est de préparer et de caractériser les particules cationiquesbiodégradables à base de cyclodextrine. Ces microparticules doivent également presenter unestructure et morphologie éponge et multifonctionnelle. L'encapsulation simultanée deplusieurs actifs cosmétiques (bien etre) et thérapeutiques (anti-inflammatoire) dans cesmicroparticules peut ouvrir de nouvelles applications une fois appliquées sur un textilespécifiquement sélectionnés pour leur fonctionnalisation. Pour atteindre cet objectif, desmicroparticules à base de polyméthacrylate cationique ont été préparés en utilisant le procédéémulsion double et diffusion de solvant suivi de l'évaporation du solvant. Des étudessystématiques ont été effectuées pour l'optimisation des paramètres du procédé ce qui apermis de contrôler la taille des particules et leur stabilité colloïdale. Une fois la taille désiréedes particules de type éponge a été obtenu, la surface d'un textile model de polyamide a étéfonctionnalisé via l'adsorption de ces particules tout en consacrent une attention particulièreaux propriétés électrocinétiques du textile avant et après fonctionnalisation en fonction d'ungrand nombre de paramètres physico-chimiques tels que; le pH, la salinité, la quantité initialede particules présente lors de l'adsorption. Enfin, l'encapsulation de la vitamine E, LIB(Lauryl Isoquinolinium Bromide), IMC (indomethacin) ainsi que l'encapsulation decomplexes de vitamine E-HPBCD, LIB-HPBCD et IMC-HPBCD dans microparticules a étéeffectuée séparément. Ces particules ont été caractérisées et la pénétration cutanée en utilisantune peau humaine a été examinée
The objective of this thesis was to prepare and characterize cyclodextrin based biodegradable,cationic and sponge like multifunctional microparticles that not only can be used for thedelivery of cosmetic and therapeutic agent (anti-inflammatory) but also can be potentiallyapplied onto specifically selected textile for their functionalization. For achieving these goals,polymethylmethacrylate based microparticles were prepared using double emulsion-diffusionsolvent evaporation technique. Systematic studies were performed for optimization of processcontrol parameters. Once desired size of sponge like particles was obtained from thesystematic study, the polyamide textile surface was functionalized with these particles whilededicating special attention to electrokinetic properties of textile as a function of variousparameters such as; particles amount present during adsorption process. Finally, encapsulationof pure vitamin E, Lauryl Isoquinolinium Bromide (LIB), Indomethacin (IMC) as well asencapsulation of complexes of vit E-Hydroxypropyl-beta-cyclodextrin (HPBCD), LIBHPBCDand IMC-HPBCD into microparticles was done separately. These particles werecharacterized for skin penetration and encapsulation efficiency
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Eudragit"

1

Blysniuk, John William. Eudragit RL/diethyl phthalate microencapsulation : analysis of experimental results. 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sugamori, Mark Eisei. Viability of islets of Langerhans microencapsulated in eudragit RL 100 for a bioartificial endocrine pancreas. 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Eudragit"

1

Aras, L., and I. Koçak. "Dilute Solution Properties of Ionomers Obtained from Eudragit-S." In Structure and Properties of Ionomers, 547–53. Dordrecht: Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-009-3829-8_51.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Quan, Ji Shan, Hu Lin Jiang, Yun Jaie Choi, Mi Kyong Yoo, and Chong Su Cho. "Thiolated Eudragit-Coated Chitosan Microspheres as an Oral Drug Delivery System." In Advanced Biomaterials VII, 445–48. Stafa: Trans Tech Publications Ltd., 2007. http://dx.doi.org/10.4028/0-87849-436-7.445.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

GUO, Jianbo, Hui XU, Shaoning WANG, Sijie ZHANG, Hiroya ABE, Xiaoyun WANG, Yanqiu ZHAO, and Makio NAITO. "Eudragit Polymer Encapsulated Hydroxyapatite Microspheres as a Carrier for the Sustained Release of Small Molecular Drugs." In Ceramic Transactions Series, 265–72. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2010. http://dx.doi.org/10.1002/9780470917145.ch38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nahler, Gerhard. "EudraCT." In Dictionary of Pharmaceutical Medicine, 68–69. Vienna: Springer Vienna, 2009. http://dx.doi.org/10.1007/978-3-211-89836-9_512.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Urbano-Ispizua, Alvaro, and Michael Hudecek. "CART Initiatives in Europe." In The EBMT/EHA CAR-T Cell Handbook, 23–28. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-94353-0_5.

Full text
Abstract:
AbstractThe efficacy of chimeric antigen receptor T cells (CARTs) in B cell neoplasms, ALL, large B cell lymphoma, and now multiple myeloma has been one of the great achievements in the fight against cancer in recent decades (Porter et al. 2011). However, there is still a need to increase the proportion of responses (especially in NHL) (Locke et al. 2019) and to decrease the proportion of relapse (especially in ALL) (Grupp et al. 2013). More importantly, currently, commercial CAR-T products are not available for T cell neoplasms, myeloid malignant haemopathies, or solid tumours. As a reflection of the necessary efforts to expand the efficacy of CARTs, more than 500 clinical trials are currently underway worldwide, mostly led by American or Chinese groups. Unfortunately, European institutions are underrepresented in these initiatives. It is our duty to push and harmonize European academic clinical trials. We identified 35 early clinical trials promoted by European groups in Eudract and ClinTrialsGov (20 February 2021). Among them, 20 are initiatives from academic institutions, and 15 are initiatives from European companies allied with European academic institutions. In this summary, CART clinical trials promoted by European academic centres or by small to medium European companies are listed. The aim is to inform European groups treating haemato-oncology diseases of the current situation in this field, facilitating the inclusion of patients in these clinical trials. We aim to support the groups promoting these studies to increase collaboration.
APA, Harvard, Vancouver, ISO, and other styles
6

"Polyacrylate (Eudragit retard) microspheres for oral controlled release of nifedipine: Formulation design and process optimization." In Pharmaceutical Technology: Controlled Drug Release Vol 2, 103–16. CRC Press, 1991. http://dx.doi.org/10.3109/9780203979099-17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Raut, Bhagyashri M., Bharati V. Bakade, and Sayali S. Bompelwar. "Design and Development of Taste Masked Formulations of Model Drug by Using Eudragit L-100: A Recent Study." In Technological Innovation in Pharmaceutical Research Vol. 9, 104–13. Book Publisher International (a part of SCIENCEDOMAIN International), 2021. http://dx.doi.org/10.9734/bpi/tipr/v9/11366d.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

"8 EudraCT." In Guide for Investigator Initiated Trials, 29–33. Basel: KARGER, 2011. http://dx.doi.org/10.1159/000328094.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Eudragit"

1

Shen, Xia-Xia, Deng-Guang Yu, Li-Min Zhu, and C. Branford-White. "Preparation and Characterization of Ultrafine Eudragit L100 fibers via Electrospinning." In 2009 3rd International Conference on Bioinformatics and Biomedical Engineering (iCBBE). IEEE, 2009. http://dx.doi.org/10.1109/icbbe.2009.5163230.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pereira, Rosa, Tommy Julianto, Kah Yuen, and Abu Abdul Majeed. "Anionic Eudragit nanoparticles as carriers for oral administration of peptidomimetic drugs." In 2006 International Conference on Nanoscience and Nanotechnology. IEEE, 2006. http://dx.doi.org/10.1109/iconn.2006.340611.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Pawłowski, Łukasz, and Andrzej Zieliński. "Electrophoretic Deposition of Chitosan/Eudragit E 100/AgNPs Coatings for Controlled Release of Antibacterial Substance." In The 7th World Congress on Electrical Engineering and Computer Systems and Science. Avestia Publishing, 2021. http://dx.doi.org/10.11159/icbes21.120.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bhatnagar, P., and K. C. Gupta. "Oral Administration of Eudragit Coated Bromelain Encapsulated PLGA Nanoparticles for Effective Delivery of Bromelain for Chemotherapy in vivo." In 2013 29th Southern Biomedical Engineering Conference (SBEC 2013). IEEE, 2013. http://dx.doi.org/10.1109/sbec.2013.32.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

BATISTA, L. M., L. J. A. DANDA, V. C. S. MELO, J. L. S. SOBRINHO, and M. F. R. SOARES. "DISPERSÕES SÓLIDAS DE PVP/VA 64 E EUDRAGIT® RS PO PARA O INCREMENTO DE SOLUBILIDADE CINÉTICA DEPOSACONAZOL." In ANAIS DO 5º ENCONTRO BRASILEIRO PARA INOVAçãO TERAPêUTICA. Galoa, 2017. http://dx.doi.org/10.17648/ebit-2017-85605.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Elkordy, Amal, Azhidhack Hadjipour, Rena-Jean Palmer, and Mohamed Zarara. "Floating Drug Delivery Systems with Xanthan Gum, Eudragit-RS PO or Lubritose SD: Nizatidine and Piracetam as Model Drugs." In 1st International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2015. http://dx.doi.org/10.3390/ecmc-1-a049.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Majeed, Abu Bakar Abdul, Rosa E. V. Pereira, Tommy B. Julianto, and Kah H. Yuen. "Enhanced oral cefotaxime sodium bioavailability after administration of cefotaxime-loaded Eudragit S100 nanoparticles and its influence on the lymphatic transport." In 2010 International Conference on Nanoscience and Nanotechnology (ICONN). IEEE, 2010. http://dx.doi.org/10.1109/iconn.2010.6045244.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Pépin, J. L., Y. Dauvilliers, V. Attali, R. Tamisier, I. Lecomte, J. M. Lecomte, P. A. Levy, and J. C. Schwartz. "Pitolisant Evaluation in Patients with OSA and Treated by NCPAP but Still Complaining of Excessive Daytime Sleepiness (EDS) Eudract n°: 2009-017248-14." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2718.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Christopoulou, A., F. Marmé, A. Oaknin, D. Lorusso, T. Safra, G. Lindahl, A. Chudecka-Glaz, et al. "P116 ATHENA (GOG-3020/ENGOT-ov45; EudraCT 2017–004557–17; NCT03522246): a randomised, double-blind, placebo-controlled, phase 3 study of the poly(ADP-Ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer (OC)." In ESGO Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/ijgc-2019-esgo.179.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Eudragit' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography